Translate this page

Disclaimer: Powered by Google Translate. Translation is a free external third-party service and MSI Australia does not control and cannot guarantee the quality or accuracy of translated content. The feature is provided for informational purposes only and use of this service is at your own risk. In all contexts the English language content on this web site, as directly provided by MSI Australia, is to be held authoritative.

/* */
MSI Australia Logo
MSI Australia logo

HomeNew Generation Pill: A Safer, More Flexible Contraceptive Choice

New Generation Pill: A Safer, More Flexible Contraceptive Choice

5 Nov, 2025 | Blog, Contraception

 

As families prepare to gather for Christmas, there’s a hidden crisis intensifying behind closed doors: reproductive violence, where someone uses coercion, manipulation, pressure or control to dictate another person’s reproductive choices, is affecting thousands of women and pregnant people across our region.

1 in 3 women globally will experience reproductive coercion in their lifetime, including sabotage of contraception, forced pregnancy, prevention or pressure related to abortion care, and financial or emotional threats linked to reproductive decisions.[1]

In Australia, around 1 in 5 women accessing abortion services report some form of coercion or control from a partner, and frontline counsellors say cases are becoming more complex, particularly during holiday periods when isolation and family pressure escalate.[2]

“Reproductive violence remains largely invisible, but it is happening right now, in homes, relationships, and families across Australia and the world,” said Grishma Bista, CEO, MSI Asia Pacific.

“No one should face abuse, pressure, or control over their reproductive choices. Access to safe, confidential care is essential, especially at a time of year when family dynamics can amplify risk.”

Holiday season increases risk

The end of the year is a peak period for relationship stress, financial pressure, travel, family expectation and isolation from support networks, all factors that increase risk of reproductive violence and reduce access to help.

MSI Australia’s psychosocial team reports a surge in women disclosing lack of control, fear, or pressure from partners in the lead up to Christmas, particularly around continuing or ending a pregnancy.

“We regularly support clients who are frightened, confused, or unsure if what they are experiencing is abuse,” said Alison Fonseca, Psychosocial Health Manager at MSI Australia.

“Reproductive violence can look like sabotaging contraception, hiding medication, pressuring someone to continue or terminate a pregnancy, or threatening to withdraw financial support. It is gendered violence, and it has devastating consequences.”

Regional impact demands regional action

Across the world, reproductive coercion is deeply connected to gender inequality, stigma, economic dependence, and access to health services. In many countries, there are no legal safeguards, limited counselling services, and severe stigma around reproductive healthcare.

“At MSI, we see resilience every day, people finding the courage to seek help, make their own decisions, and protect their future,” Ms Bista said.

“But access to safe pathways must be funded, protected and strengthened.”

Campaign launching: Help us support safety, choice and care

This Christmas, MSI is launching a donation campaign to support people experiencing reproductive violence, here and overseas.

Funds raised will:

  • Provide emergency psychosocial support including counselling
  • Cover the cost of abortion or contraception care for people facing coercion
  • Support local services in countries where reproductive violence is rarely acknowledged

Every donation, large or small, helps someone make a decision free from control, fear and pressure.

“No one should be forced into or out of a pregnancy,” Ms Fonseca said.

“With community support, we can make sure reproductive choices belong to the person, not their partner, not their family, and not their circumstances.”

Key facts

  • 1 in 5 Australian women seeking abortion report pressure or coercion related to pregnancy decisions
  • Only 12 out of 43 Asia Pacific countries have legislation enshrining the right to choose the number, timing, and spacing of children [3]
  • Reproductive violence is one of the least recognised forms of gender-based violence, despite being reported in clinical and counselling settings worldwide [4]
  • Family violence is consistently one of the high-recorded months for family violence incidents [5]

[1] World Health Organisation. (2021)

[2] MSI Australia. (2020). Hidden Forces: Shining a light on reproductive coercion white paper

[3] IPPF. (2023). Asia Pacific Contraception Policy Atlas

[4]  Tarzia & McKenzie. (2024). Reproductive coercion and abuse in intimate relationships: Women’s perceptions of perpetrator motivations

[5] Crime Statistics Agency. (2025). Family Incidents

Ends

For more information contact Anna Jabour on 0403 322 992

 

Pain & Recovery Time for Surgical Abortion vs Medical Abortion

At MSI Australia, we believe every person should have access to contraception that fits their health needs and lifestyle. Slinda is a new generation progesterone-only pill (POP) designed to be easier to use and more flexible than traditional options. With its advanced formulation, it offers a reliable choice that may be suitable for a wider range of women seeking effective and convenient contraception.

Why it stands out

This new generation pill is ideal if:

  • You can’t take estrogen (due to migraines, high blood pressure, or clotting risks)
  • You’re breastfeeding
  • You’re a smoker and older than 35
  • You want high efficacy (99% with perfect use) with fewer side effects

Unlike older combined pills, this pill:

  • Gives more predictable periods (lighter or even no bleeding for many)
  • Has a 24-hour “missed pill” window (vs. 3 hours with traditional POPs)

Who can use it?

This pill can be a game-changer for women who’ve struggled with other contraceptives, including those who:

  • Have high blood pressure, migraines with aura or a history of blood clots
  • Are breastfeeding
  • Smoke
  • Want a reversible, daily option without estrogen

Note: This pill isn’t recommended if you currently have an active blood clot.

How to start

Starting Slinda is simple, but timing depends on your current contraception:

1. If you’re new to hormonal contraceptives:

  • Start on Day 1 of your period (immediate protection).
  • Other times: Take 7 active pills (white tablets) before relying on it. Use condoms during this time.

2. Switching from another pill or ring?

  • Start the day after your last active combined pill/ring (no gap = no extra protection needed).
  • If there’s a gap longer than 1 day, take 7 active pills + use condoms.

3. After childbirth, IUD removal, or implant removal:

  • Start immediately after removal/injection due date for seamless protection.
  • If it’s been >28 days postpartum, take 7 active pills + use condoms (and take a pregnancy test first).

What if I miss a pill?

Under 24 hours late: Take it ASAP and continue as normal. You’re still protected.

Over 24 hours late: Follow the missed-pill rules (depends on where you are in your pack).

Suffering from vomiting or diarrhea: Treat as a missed pill – absorption may be affected.

Your questions answered?

Can I use this pill while breastfeeding?
Yes! It is safe and won’t affect milk supply.

Will my periods change?
Likely. Many women have lighter periods or none at all (50% stop within a year). Breakthrough bleeding may occur but is usually light.

Is it reversible?
Completely. Stop anytime – your cycle returns quickly.

Is it covered by PBS?
Yes, it became avaialable on the PBS in May 2025.

Why choose this new generation pill?

  • Safe for more women (no estrogen = fewer restrictions)
  • Fewer side effects than older pills
  • Flexible timing (24-hour window for missed pills)
  • Discreet and reversible

Ready to see if its right for you? Our clinicians can help you decide.
Book a consultation with us on 1300 003 707. 

Content reviewed by Dr Philip Goldstone, Medical Director of MSI Australia.